Tryptophan
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Tryptophan: From Nutritional Amino Acid to Restless Legs Syndrome
One-Sentence Summary
Tryptophan is an essential amino acid. In South Africa it is registered as a component of parenteral nutrition and dialysis solutions. The TxGNN model predicts it may be useful for restless legs syndrome (RLS). There are currently 0 registered clinical trials and 8 publications on this direction, and only 3 of them directly concern tryptophan. Two of those are 1980s studies with no abstract available, and the third is a 1992 narrative review.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA data supplied (registered products are infusion and nutrition solutions) |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L3 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Tryptophan is the dietary precursor of serotonin and melatonin. RLS is thought to involve dysregulated central dopaminergic and serotonergic signalling, so a link through monoamine synthesis is plausible.
The link is unproven. The available literature shows an association between monoamine pathways and RLS, not that giving tryptophan treats it. A pharmacovigilance study and a case report suggest that serotonergic antidepressants and lithium can induce or worsen RLS. The effect of raising serotonin precursor supply could therefore go the wrong way.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3953904 | 1986 | Clinical study (design not verified) | Am J Psychiatry | “L-Tryptophan in the treatment of restless legs syndrome”. Only the title is available, so results cannot be summarised. |
| 3659737 | 1987 | Clinical/pharmacologic study (design not verified) | Sleep | Periodic leg movement with L-dopa, 5-hydroxytryptophan and L-tryptophan. No abstract available. |
| 1305630 | 1992 | Review | Int J Neurosci | L-tryptophan in neuropsychiatric disorders. Serotonin is linked to mood, sleep and motor control, and abnormalities are implicated in several movement disorders. |
| 33836477 | 2021 | Systematic review/meta-analysis | Sleep Med Rev | RLS in chronic liver disease. Elevated tryptophan is one proposed contributor to sleep disturbance. Not a tryptophan treatment study. |
| 36897462 | 2023 | Case series | Neurol Sci | RLS in DNAJC12 deficiency, an inherited disorder of dopamine and serotonin synthesis. Supports a monoamine link to RLS. |
| 32546134 | 2020 | Pharmacovigilance study | BMC Psychiatry | Antidepressant-associated movement disorders in the WHO database. This is a safety signal for serotonergic drugs. |
| 1777530 | 1991 | Case report | Biol Psychiatry | RLS induced by lithium. No abstract available. |
| 2881477 | 1987 | Review | Am Fam Physician | General diagnosis and treatment of insomnia. Only tangentially related to RLS. |
South Africa Market Information
Ten registrations were found. The first five are listed below. Manufacturer and approved indication text were not supplied. No Essential Medicines List status was supplied.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| 37/34/0243 | Nutrineal PD4 with 1.1% amino acids 2.5L | Infusion |
| 33/10.2.1/0271 | Adco-ipratropium (ni201) | Vial |
| 38/34/0172 | Extraneal 2L single bag | Infusion |
| 37/25.2/0503 | Oliclinomel N6 900E 2000ml | Infusion |
| 41/25/0757 | Nutriflex Lipid Peri | Infusion |
All the registered products are nutrition or dialysis solutions, and none is an oral tryptophan product. This limits how directly any RLS use could be supported by current registrations. The ipratropium entry looks like a possible ingredient-matching artefact and should be checked.
Safety Considerations
- Direction-of-effect concern: Serotonergic antidepressants and lithium have been reported to induce or worsen RLS (PMID 32546134, 1777530). Whether a serotonin precursor could do the same is unknown, but it needs to be examined before any clinical testing.
Please refer to the SAHPRA-approved Professional Information (PI) for other safety information, including warnings, contraindications and drug interactions. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link is plausible, but there are no registered trials and no verifiable clinical data. The only direct tryptophan-RLS papers date from 1986–1987, and no results are available for them. There is also an unresolved concern that serotonergic modulation might worsen RLS.
To proceed, the following is needed:
- Full texts of PMID 3953904 and 3659737, to establish design, dose and outcomes
- Mechanism of action data (MOA) from DrugBank
- SAHPRA package insert warnings and contraindications for the registered products
- A structured literature review of serotonergic effects in RLS, to clarify the direction of effect
- A review of the registered products, to identify whether any oral tryptophan formulation exists in South Africa
- If the above is favourable, a small controlled pilot with clear RLS outcome measures (e.g. IRLS scale)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.